AMGA-family research and analytics limited liability company
One uniform surface for comparison; detailed evidence is below.
The score summarizes assessed evidence; evidence coverage is reported separately.
AMGA Inc. accounting categories are parent-association context only and must not be treated as AMGA Analytics LLC revenue.
Primary constituency: AMGA-member medical groups and integrated systems; individual physicians are not shown as a separate governed constituency.
Physician alignment: Role dependent; strongest for physician executives and system-level improvement, not demonstrated for broad individual-physician representation.
Funding model: Standalone funding model and concentration are not publicly established.
Primary influence: AMGA executive and research leadership operationally; member organizations, project funders, and data partners influence individual work.
AMGA Analytics LLC appears to be a functioning AMGA-family research and analytics entity with identifiable research leadership, public safeguards, partnerships, and measurable project outputs. Public evidence does not establish its standalone revenue, payer mix, governing authority, related-entity transfers, or contract concentration. A Brown University filing identifies one $157,451 subcontract, while commercial and data relationships are otherwise largely unquantified. For that reason the C-equivalent score is indicative only, the entity is excluded from peer ranking, and the page should be used as an affiliate drill-down rather than as a fully comparable organization grade.
One sentence: AMGA Analytics shows credible research activity but lacks enough standalone financial and governance disclosure for a defensible peer ranking.
Every organization uses the same twelve evidence sections and order.
AMGA’s official history says Analytics LLC joined the AMGA family in 2001 and that AMGA’s divisions were aligned around a unified mission in 2016. [1]
No standalone LLC website, current operating agreement, public entity profile, or clear legal-purpose statement was found in the sources reviewed.
Moderate–high for AMGA-family affiliation and function; low for formal legal scope and ownership.
Elizabeth Ciemins, PhD, MPH, MA, is the publicly listed Chief Research Officer. Jerry Penso, MD, MBA, is AMGA President and CEO. Beth Averbeck, MD, is the 2026 AMGA board chair. [3] [5]
The dated January 2026 board release and board page name Beth Averbeck as chair, while AMGA’s contact page still labels Larry Tatum as chair. No LLC-specific manager or board was found. [3] [4] [5]
High for current parent and research titles; low for formal LLC authority.
| Person / role | Documented current title | Authority relevant to LLC | FY2024 AMGA Inc. compensation context | Notes |
|---|---|---|---|---|
| Beth Averbeck, MD | Chair, AMGA Board of Directors | Parent-level governance; direct LLC authority not established. | Board service reported $0 in FY2024, when listed as treasurer. | Current chair verified by Jan. 8, 2026 release and board page. |
| Jerry Penso, MD, MBA | President and Chief Executive Officer, AMGA | Strongest publicly visible executive influence; legal LLC office not identified. | $768,708 organization; $7,907 related; $147,535 other. | AMGA board page says CEO serves as a nonvoting board member. |
| Elizabeth Ciemins, PhD, MPH, MA | Chief Research Officer | Directly documented operational leadership of Research and Analytics. | $344,319 organization; $0 related; $53,638 other. | No LLC-specific employment agreement or delegated authority disclosed. |
| Carrie Hanlon, CPA | Chief Financial Officer, AMGA | Likely parent finance oversight; LLC-specific responsibility not documented. | $269,253 organization; $0 related; $30,945 other. | Standalone LLC statements not published. |
| Chester A. Speed, JD, LLM | Chief Policy Officer, AMGA | Parent political and policy influence; direct LLC political role not established. | $466,682 organization; $0 related; $86,863 other. | AMGA also lists government-relations staff. |
| LLC manager / legal officers | Not publicly identified in reviewed sources | Unknown. | Not available. | Operating agreement and state entity record were not available in the accessible source set. |
Compensation is from AMGA Inc.’s FY2024 Form 990 and is not attributed to work for the LLC. [10]
Brown University’s TY2022 filing lists a $157,451 subcontract grant to AMGA Analytics LLC. Exact Sciences-supported research and commercial/data relationships are also documented, mostly without amounts. [8] [11]
No standalone LLC audited financial statements, revenue total, customer concentration, receivables schedule, grant register, or related-party transfer schedule was located.
High for the Brown payment; moderate for documented project relationships; low for total funding mix.
| Payer or revenue class | Public evidence | Quantified amount | Assessment |
|---|---|---|---|
| Individual physician dues | No LLC-specific record found. | Unknown | Not established. |
| Group-paid / enterprise-paid dues | AMGA has organizational membership, but no LLC allocation is public. | Unknown | Do not infer. |
| Hospitals / health systems / academic systems | Member participation and data contributions are documented; direct LLC payments are not. | Unknown | Participation ≠ payment. |
| Physician groups / management companies / joint ventures | No LLC-specific payment schedule found. | Unknown | Not established. |
| Insurers / PBMs / pharma / devices | Exact Sciences-supported work is documented; other partner relationships exist at AMGA level. | Mostly undisclosed | Entity allocation and direction of payment unclear. |
| University / research subcontracts | Brown University subcontract grant. | $157,451 | Directly documented. |
| Commercial data / analytics relationships | Lightbeam exclusive partnership and Optum Labs data relationship. | Undisclosed | Financial terms not public. |
| Government grants / contracts | No LLC-specific amount established in this review. | Unknown | Not established. |
| Investment, rent, royalties, advertising, exhibits | No standalone LLC detail found. | Unknown | Not established. |
| Related-entity transfers | AMGA entities work together, but transfer amounts were not accessible. | Unknown | Do not combine entities. |
Data age: the Brown payment appears in a TY2022 filing and is useful as proof of one payer relationship, not as evidence of the current or dominant funding mix.
The public record identifies at least one university payer and several project or data partners, but it does not disclose the LLC’s total revenue or mutually exclusive payer classes.
AMGA Inc.’s accounting categories cannot be used as a substitute. “Program services” does not identify customers, and “contributions” does not identify donors or recipient entity.
High that a payer pie chart would overstate the evidence.
| Question | Evidence-based answer | Confidence |
|---|---|---|
| Who primarily funds the organization? | The available records do not establish a primary funder. | High confidence in non-assessability. |
| How much is traceable to individual physicians? | No amount is established. | Moderate. |
| How much is traceable to hospitals or health systems? | No direct payment amount is established. | Moderate. |
| How much is traceable to groups or joint ventures? | No direct payment amount is established. | Moderate. |
| How much is traceable to insurers, pharma, devices, or commercial partners? | Project and commercial relationships are documented, but amounts and LLC allocation are mostly undisclosed. | Moderate. |
| How much remains unknown? | Cannot be expressed as a dollar amount or percentage because the total denominator is not public. | High. |
| Largest identifiable payer class? | Not calculable. Brown University is the largest quantified direct payer found, but it is not proven to be the largest actual payer. | High. |
| Top-one / top-three concentration? | Not calculable. | High. |
AMGA’s history distinguishes AMGA, its Foundation, Analytics LLC, and Consulting while describing them as one family aligned around a unified mission. [1]
The reviewed source set did not reveal a current LLC ownership percentage, operating agreement, services agreement, consolidated audit note, or intercompany transfer schedule.
High that the entities must be kept separate; low for exact legal ownership and money flows.
501(c)(6) trade association. Shared address, executives, brand, and parent-level financial filing. Exact LLC ownership not verified.
Target entity. Formed in 2001 according to AMGA history. EIN 54-2020131 appears in Brown filing.
Separate charitable affiliate. Conducts quality initiatives and receives sponsor support; Foundation receipts must not be counted as LLC revenue without a transfer record.
Separate AMGA division/business line. No payment flow to or from the LLC was identified in this review.
Money-flow rules applied
| Person / institution | Influence channel | Classification | Evidence and limit |
|---|---|---|---|
| AMGA executive and research leadership | Strategy, staffing, research operations, finance, brand | Strong inference | Named roles and integrated staff are public; LLC legal delegations are not. |
| Elizabeth Ciemins and Research & Analytics team | Study design, partnerships, data, publication, implementation | Directly documented | Chief Research Officer and team listed publicly; publications and programs corroborate activity. |
| AMGA Board | Parent association governance and direction | Strong inference | Parent governance is documented; direct LLC authority is unknown. |
| AMGA member groups and health systems | Data access, recruitment, implementation, practical priorities | Directly documented | AMGA says members participate in studies and supply real-world implementation settings. [6] |
| Brown University | Research funding | Directly documented | $157,451 subcontract grant; no proof of ongoing or dominant influence. |
| Exact Sciences | Project sponsorship | Directly documented | Supported CRC research; amount and contractual controls not public. [8] |
| Lightbeam Health Solutions | Exclusive analytics/population-health platform relationship | Directly documented | Exclusive partnership and data access are public; payment, data-rights, and termination terms are not. [7] |
| Optum Labs | Large EHR and claims data relationship | Directly documented | AMGA describes warehouse access; financial direction is not disclosed. [6] |
| AMGA public-policy leadership | Parent advocacy and political agenda | Unknown for LLC | AMGA lists a Chief Policy Officer and government-relations team; direct LLC lobbying activity was not established. |
| Any single dominant commercial actor | Financial control | Unknown | No payer denominator or contract register supports such a conclusion. |
Greatest operational influence: AMGA executive/research leadership, based on integrated roles and branding. Greatest financial influence: indeterminate. Greatest political influence: AMGA’s parent policy leadership, while direct LLC political activity remains unestablished.
Research, measure development, learning collaboratives, and point-of-care risk work are substantively aligned with improving care delivery and patient outcomes.
Sponsor and platform relationships create potential incentives. Public disclosures do not reveal all contract terms, publication rights, data rights, or sponsor control.
Moderate–high for alignment of visible work; low for unobserved project selection and financial incentives.
| Stated commitment | Date / source | Relevant action or omission | Assessment | Confidence |
|---|---|---|---|---|
| Improve patients’ lives through integrated delivery | Current AMGA mission [2] | Research on diabetes risk, ASCVD care, CRC follow-up, immunization, and population health. | Aligned | Moderate–high |
| Translate evidence into practice | Current partnership page [6] | Mixed-method studies, measure development, and learning collaboratives with member organizations. | Aligned | High |
| Protect research integrity | Policies dated June–September 2022 [9] | Human-subject, adverse-event, FCOI policy, and disclosure form are published. | Supported | Moderate |
| Represent physicians through high-performing systems | 2026 AMGA description [3] | Member systems and groups participate; individual segment-level support and voting are not disclosed for the LLC. | Not assessable for LLC | Low |
| Accountability for sponsor influence | Not a clearly stated public promise | Some sponsors and partners are named, but amounts and detailed contractual safeguards are generally absent. | Partially demonstrated | Moderate |
Documented outcomes
AMGA’s constituency is organization-based: multispecialty groups, integrated delivery systems, ACOs, and similar entities. Research engages member organizations across the country. [3] [6]
Total physicians practicing in member organizations does not establish individual membership, voting, active participation, financial contribution, or equal representation by segment.
High for organizational constituency; low for segment-level breadth and LLC governance representation.
| Segment | Evidence | Assessment |
|---|---|---|
| Primary care | Current board chair is a primary-care medical director; 2026 diabetes study occurred in primary care. | Some support demonstrated; population-wide breadth unknown. |
| Medical specialties | Multispecialty groups are a core constituency; research spans chronic disease and population health. | Supported at organization level. |
| Surgical / procedural specialties | Board includes procedural specialists and systems, but LLC program participation by specialty is not reported. | Unknown. |
| Independent practice | Some AMGA member groups may be physician-led or independent, but no LLC-specific participation or benefit data were found. | Unknown. |
| Hospital-employed physicians | Integrated health systems are prominent members and board institutions. | Strong organizational presence; individual support not measured. |
| Academic physicians | Academic systems and university collaborations appear in leadership and research. | Some support demonstrated. |
| Rural / community physicians | No segment-level analytics, participation, or governance data found. | Unknown. |
| Residents, fellows, students | No LLC-specific representation data found. | Unknown. |
| Women, early-career, retired physicians | No LLC-specific participation, voting, or governance metrics found. | Unknown. |
Broad-support conclusion: The evidence suggests the operation is designed primarily for organized medical groups and integrated systems. It does not establish equal support for every physician segment, especially individual, small independent, rural, trainee, or retired physicians.
No reliable record of a material government enforcement action, final judgment, fraud finding, campaign-finance violation, or licensing action against AMGA Analytics LLC was found in the open-web sources reviewed. [14] [15]
AMGA publishes human-subject protections, adverse-event procedures, a research FCOI policy, and an investigator disclosure form. [9]
Low. This was an open-source review, not a comprehensive PACER, state-court, arbitration, insurance, employment, or regulatory-record audit.
| Area | Finding | Limit |
|---|---|---|
| Government enforcement | No material action located under the exact entity name. | Name variants, sealed matters, and nonindexed records may be missed. |
| Civil / criminal proceedings | No material final judgment located under the exact entity name. | No comprehensive paid docket search was performed. |
| Antitrust / fraud / false claims | No reliable adverse finding located. | Absence of a located record is not proof of absence. |
| Campaign finance / lobbying | AMGA has a parent-level policy and government-relations function; direct LLC political spending or lobbying was not established. | Affiliate and state-level records may require separate searches. |
| Research ethics | Published safeguards address human subjects, adverse events, and investigator financial conflicts. | Public materials do not establish how often disclosures occur, how conflicts are resolved, or whether every commercial project is covered. |
| Governance data quality | Current AMGA chair information is inconsistent across official pages. | Treated as a freshness/control issue, not misconduct. |
The legal score is favorable but low-confidence and should not be described as a “clean bill of health.” A comprehensive legal diligence review could materially change it.
Dimensions with insufficient evidence are marked NE and excluded from the score denominator rather than scored as zero.
Assessable weight: 60 of 100 points. Earned: 42. Normalized score: 42 ÷ 60 × 100 = 70.0.
C: mixed record or meaningful unanswered questions. This is a provisional evidence grade, not a moral verdict.
| Dimension | Score | Grade | Evidence confidence | One-sentence conclusion | Key unknown |
|---|---|---|---|---|---|
| Financial Transparency and Source Identification | 6 / 15 | F | High | Some entity and payment evidence exists, but standalone financial and payer disclosure is poor. | Total revenue, payer roster, contracts, transfers. |
| Funding Independence and Concentration Risk | NE | NE | Low | No denominator supports a concentration judgment. | Largest payers and contract dependence. |
| Mission-to-Action Alignment | 17 / 20 | B | Moderate–high | Visible research and improvement work generally aligns with the stated mission. | Unpublished project-selection and sponsor terms. |
| Physician or Member Governance and Representation | NE | NE | Low | Parent governance is visible; LLC governance and member authority are not. | Manager, board, voting and delegated authority. |
| Breadth of Support Across Physician Segments | NE | NE | Low | Support is visible for organized systems, but segment breadth cannot be measured. | Eligible, enrolled, voting, active and represented counts. |
| Leadership, Conflict Management, and Accountability | 7 / 10 | C | Moderate | Named leaders and research safeguards are favorable, offset by unclear LLC authority and limited disclosure. | LLC officers, all-project COI and accountability reports. |
| Legal, Regulatory, and Ethical Record | 8 / 10 | B | Low | No material adverse record was located and safeguards are published, but search coverage is incomplete. | Comprehensive dockets, settlements, investigations. |
| Outcomes and Public Accountability | 4 / 5 | B | Moderate–high | Research outputs and outcome signals are visible, though no standalone LLC annual outcomes report was found. | Entity-specific portfolio, negative/null results, sponsor-level outcomes. |
Status indicators
The operation is described publicly through AMGA’s integrated brand, while the legal LLC’s standalone financial and governance record is sparse.
Leadership and program pages are current through 2026, parent financial context covers FY2024, and the only quantified LLC payment found is from TY2022.
Public web sources cannot reveal private contracts, nonpublic audits, sealed matters, internal board minutes, or undisclosed conflicts.
Information most likely to change the assessment
Trust conclusion: The strongest reasons to trust are visible expertise, research safeguards, and demonstrated outputs. The strongest reasons for caution are financial opacity, uncertain LLC governance, and undisclosed commercial terms. The evidence supports cautious engagement with targeted diligence, not a categorical endorsement or accusation.
Publication status: Public review. A last-link check and final editorial approval are required before each release.
Organization review: The reviewed organization did not approve, edit, or veto the score. A factual correction process is described on the Blair Compass methodology and corrections pages.
Scope: Verification is limited to publicly accessible records. Private contracts, nonpublic minutes, sealed proceedings, and undisclosed conflicts are outside the available evidence.
Source rule: Primary and official records were preferred. Accounting categories were not converted into payer identities. Related entities were kept separate. Allegations were not treated as findings.
Verification: current leaders and major financial arithmetic were checked for this publication batch. Material corrections and future updates follow the published verification process.
